Abstract Library

#3129 Colorectal NECs and MANECs: A monocenter pilot retrospective analysis

Introduction: Poorly-differentiated neuroendocrine carcinomas (NECs) and mixed adeno-neuroendocrine carcinomas (MANECs) are rare and aggressive neoplasms whose tumorigenesis pathways are still unknown and clinical management not universally shared.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Laffi A, Spada F, Ranghiero A, Pisa E, Barberis M,

Keywords: mutational, genetic, neuroendocrine, NEC, MANEC, carcinogenesis, colorectal,

#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus

Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Cella C, Barberis M, Spad F, Pisa E, Laffi A,

Keywords: Everolimus, MET, RET,

#513 Correlation Between mTOR Pathway and Clinical Outcomes in Patients with Well-Differentiated Neuroendocrine Tumors Treated with Everolimus

Introduction: Everolimus has been studied in preclinical and clinical settings, showing it to be active and effective. Tumors exhibiting the constitutively activated phosphatidylinositol-3-kinase-AKT-mTOR (PI3K/AKT/mTOR) pathway, are potentially susceptible to mTOR inhibitors. Even though Everolimus is both an antiproliferative and anti-angiogenic drug, we do not know the possible prognostic or predictive role of p-mTOR pathway.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Spada F, Pisa E, Lorizzo K, Barberis M, Fazio N,

Keywords: mTOR,

#364 Platinum-based chemotherapy in patients with advanced neuroendocrine carcinomas: an Italian retrospective multicenter analysis

Introduction: Conventional chemotherapy has not yet a well defined role in well/moderately differentiated (WD) neuroendocrine carcinomas (NECs).

Conference:

Presenting Author:

Authors: SPADA F, SCARABELLI L, LORIZZO K, PELOSI G, BARBERIS M,

Keywords: neuroendocrine, ERCC1, Ki 67 ,